Company Overview
MeiraGTx (MGTX) is a clinical-stage gene therapy company targeting serious conditions with no existing curative options or even acceptable therapeutic approaches. It has four clinical-stage programs for ocular conditions, one for Parkinson's disease, and one for radiation-induced xerostomia. The company's most advanced indication, X-Linked Retinitis Pigmentosa (XLRP), recently reported clinical data and announced that they will be progressing to a PhIII trial. MGTX has already licensed its treatment for XLRP as well as two additional ocular conditions to Janssen (JNJ). In addition to their clinical programs, MGTX has a